23 Result(s)
within
Alexander H. Schmidt
-
Protocol
Full-Length Characterization of Novel HLA-DRB1 Alleles for Reference Database Submission
The prerequisite for successful HLA genoty** is the integrity of the large allele reference database IPD-IMGT/HLA. Consequently, it is in the laboratories’ best interest that the data quality of submitted no...
-
Protocol
Submitting Novel Full-Length HLA, MIC, and KIR Alleles with TypeLoader2
The Immuno Polymorphism Database (IPD) plays a pivotal role for immunogenetics. Due to technical limitations, genoty** often focuses on specific key regions like the antigen recognition domain (ARD) for HLA ...
-
Article
Open AccessSmall volume bone marrow aspirates with high progenitor cell concentrations maximize cell therapy dose manufacture and substantially reduce donor hemoglobin loss
Bone marrow (BM) transplantation is a life-saving therapy for hematological diseases, and the BM harbors also highly useful (progenitor) cell types for novel cell therapies manufacture. Yet, the BM collection ...
-
Article
Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020—Report from World Marrow Donor Association
-
Article
Open AccessCorrection to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
-
Article
Open AccessDR2S: an integrated algorithm providing reference-grade haplotype sequences from heterozygous samples
High resolution HLA genoty** of donors and recipients is a crucially important prerequisite for haematopoetic stem-cell transplantation and relies heavily on the quality and completeness of immunogenetic refere...
-
Article
Open AccessStem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS
The COVID-19 pandemic has serious implications also for patients with other diseases. Here, we describe the effects of the pandemic on unrelated hematopoietic stem cell donation and transplantation from the pe...
-
Article
Open AccessSalvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
We conducted a prospective clinical trial to investigate the safety and efficacy of plerixafor (P) in allogeneic peripheral blood stem cells (PBSC) donors with poor mobilization response to standard-dose granu...
-
Article
Correction: HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort
The original version of this Article contained an error in the spelling of the author Denis Poddubnyy, which was incorrectly given as Denis Podubbnyy. This has now been corrected in both the PDF and HTML versi...
-
Article
HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort
We aimed to assess the mRNA expression of MHC class 1-related molecules in ankylosing spondylitis (AS) patients vs healthy controls (HCs) and, subsequently, if the absence of HLA-C*07 is associated with geneti...
-
Article
Open AccessVery low error rates of NGS-based HLA ty** at stem cell donor recruitment question the need for a standard confirmatory ty** step before donor work-up
-
Article
The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation – a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR
Hematological malignancies can be cured by unrelated donor allogeneic HSCT and outcomes are optimized by high-resolution HLA matching at HLA-A, -B, -C, -DRB1 and -DQB1 (10/10 match). If a 10/10 match is unavai...
-
Article
Open AccessAncient DNA study reveals HLA susceptibility locus for leprosy in medieval Europeans
Leprosy, a chronic infectious disease caused by Mycobacterium leprae (M. leprae), was very common in Europe till the 16th century. Here, we perform an ancient DNA study on medieval skeletons from Denmark that sho...
-
Protocol
HLA Haplotype Frequency Estimation from Real-Life Data with the Hapl-o-Mat Software
HLA haplotype frequencies are of use in a variety of settings. Such data is typically derived either from family pedigree data by targeted ty** or statistical analysis of large population-specific genotype s...
-
Protocol
Full-Length HLA Class I Genoty** with the MinION Nanopore Sequencer
Nanopore sequencing, a paradigm change in sequencing technologies, offers a new cost-effective and scalable platform for HLA genoty**. Among the new generation of high-throughput sequencing technologies, the...
-
Article
Open AccessHapl-o-Mat: open-source software for HLA haplotype frequency estimation from ambiguous and heterogeneous data
Knowledge of HLA haplotypes is helpful in many settings as disease association studies, population genetics, or hematopoietic stem cell transplantation. Regarding the recruitment of unrelated hematopoietic ste...
-
Article
Open Access2.7 million samples genotyped for HLA by next generation sequencing: lessons learned
At the DKMS Life Science Lab, Next Generation Sequencing (NGS) has been used for ultra-high-volume high-resolution genoty** of HLA loci for the last three and a half years. Here, we report on our experiences...
-
Article
SFC-MS/MS as an orthogonal technique for improved screening of polar analytes in anti-do** control
HPLC is considered the method of choice for the separation of various classes of drugs. However, some analytes are still challenging as HPLC shows limited resolution capabilities for highly polar analytes as t...
-
Article
Open AccessABO allele-level frequency estimation based on population-scale genoty** by next generation sequencing
The characterization of the ABO blood group status is vital for blood transfusion and solid organ transplantation. Several methods for the molecular characterization of the ABO gene, which encodes the alleles tha...
-
Article
Open AccessSimulation shows that HLA-matched stem cell donors can remain unidentified in donor searches
The heterogeneous nature of HLA information in real-life stem cell donor registries may hamper unrelated donor searches. It is even possible that fully HLA-matched donors with incomplete HLA information are no...
